These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24219051)

  • 21. Calculation of quality adjusted life years in the published literature: a review of methodology and transparency.
    Richardson G; Manca A
    Health Econ; 2004 Dec; 13(12):1203-10. PubMed ID: 15386669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health utilities in gynecological oncology and mastology in Germany.
    Hildebrandt T; Thiel FC; Fasching PA; Graf C; Bani MR; Loehberg CR; Schrauder MG; Jud SM; Hack CC; Beckmann MW; Lux MP
    Anticancer Res; 2014 Feb; 34(2):829-35. PubMed ID: 24511019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Evaluation of quality of life in oncology].
    Radosavljević D; Jelić S; Bosnjak S
    Srp Arh Celok Lek; 1997; 125(9-10):303-10. PubMed ID: 9340804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Social valuation of EQ-5D health states: the Chilean case.
    Zarate V; Kind P; Valenzuela P; Vignau A; Olivares-Tirado P; Munoz A
    Value Health; 2011 Dec; 14(8):1135-41. PubMed ID: 22152184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-related quality of life after stroke: review of the literature and implications for future research.
    Tseng MC; Lin HJ
    Acta Neurol Taiwan; 2007 Mar; 16(1):7-12. PubMed ID: 17486727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-utility estimates in depression: does the valuation method matter?
    Jonkers CC; Lamers F; Evers SM; Bosma H; Van Eijk JT
    J Ment Health Policy Econ; 2010 Dec; 13(4):189-97. PubMed ID: 21368342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are quality of life, patient preferences, and costs realistic outcomes for clinical trials?
    Rusthoven JJ
    Support Care Cancer; 1997 Mar; 5(2):112-7. PubMed ID: 9069610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measuring the cost-effectiveness of cancer care.
    Schulman KA; Yabroff KR
    Oncology (Williston Park); 1995 Jun; 9(6):523-30, 533; discussion 533-8. PubMed ID: 8719099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of health utility data when some subjects attain the upper bound of 1: are Tobit and CLAD models appropriate?
    Pullenayegum EM; Tarride JE; Xie F; Goeree R; Gerstein HC; O'Reilly D
    Value Health; 2010; 13(4):487-94. PubMed ID: 20230549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measurement of utilities and quality-adjusted survival.
    Weeks J
    Oncology (Williston Park); 1995 Nov; 9(11 Suppl):67-70. PubMed ID: 8608058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Indirect comparisons in cost-effectiveness analysis: are we being naïve?
    Martin-Broto J
    Clin Transl Oncol; 2015 Jan; 17(1):85-6. PubMed ID: 25413140
    [No Abstract]   [Full Text] [Related]  

  • 32. A taxonomy of the uses of health-related quality-of-life instruments in cancer care and the clinical meaningfulness of the results.
    Osoba D
    Med Care; 2002 Jun; 40(6 Suppl):III31-8. PubMed ID: 12064756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations.
    Matza LS; Stewart KD; Lloyd AJ; Rowen D; Brazier JE
    Value Health; 2021 Jun; 24(6):812-821. PubMed ID: 34119079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. QALYs: some challenges.
    Nord E; Daniels N; Kamlet M
    Value Health; 2009 Mar; 12 Suppl 1():S10-5. PubMed ID: 19250125
    [No Abstract]   [Full Text] [Related]  

  • 35. Health state values from multiattribute utility instruments need correction.
    Nord E
    Ann Med; 2001 Jul; 33(5):371-4. PubMed ID: 11491196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. QALYs: the basics.
    Weinstein MC; Torrance G; McGuire A
    Value Health; 2009 Mar; 12 Suppl 1():S5-9. PubMed ID: 19250132
    [No Abstract]   [Full Text] [Related]  

  • 37. How to identify and treat data inconsistencies when eliciting health-state utility values for patient-centered decision making.
    Triantaphyllou E; Yanase J
    Artif Intell Med; 2020 Jun; 106():101882. PubMed ID: 32593392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical trials referral resource. Health-related quality of life in cancer clinical trials.
    Trimble EL; Rowland J; Varricchio C; Gore-Langton RE
    Oncology (Williston Park); 2001 May; 15(5):601-3, 606-8, 611. PubMed ID: 11396355
    [No Abstract]   [Full Text] [Related]  

  • 39. Constructing indirect utility models: some observations on the principles and practice of mapping to obtain health state utilities.
    McCabe C; Edlin R; Meads D; Brown C; Kharroubi S
    Pharmacoeconomics; 2013 Aug; 31(8):635-41. PubMed ID: 23832811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of QALYs in clinical and patient decision-making: issues and prospects.
    Kind P; Lafata JE; Matuszewski K; Raisch D
    Value Health; 2009 Mar; 12 Suppl 1():S27-30. PubMed ID: 19250128
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.